Navigation Links
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Date:1/18/2012

SAN DIEGO, Jan. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering, Piper Jaffray & Co. and Leerink Swann LLC are acting as co-managers for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on December 29, 2010. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's Web site at http://www.sec.gov. Copies of the preliminary prospectus supplement relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com, or from Deutsche Bank Securities Inc., Attention: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311-3901, or by telephone at 800-503-4611, or by email at Prospectus.cpdg@db.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to Neurocrine's expectations regarding the completion, timing and size of its proposed public offeringAmong the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with Neurocrine's business and finances in general, and the other risks described in Neurocrine's annual report on Form 10-K for the year ended December 31, 2010 and quarterly report on Form 10-Q for the quarter ended September 30, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Mourns the Passing of Founder and Board Member Wylie Vale, Ph.D.
2. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
4. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
8. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
9. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
10. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... "Success Files," a short- ... Alzheimer’s. Alzheimer’s is a disease estimated to affect the lives of more than ... the Alzheimer’s Association, a leading voice in the fight for cure and research ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released app Smart ... to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, or any ... find clothing at discounted prices. Apart from this, Smart Mart has emphasized upon ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic ... Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as ... is an annual award that was started in 2003 to salute young achievers ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... right or exercise more try taking a more holistic approach and use natural ... new Amazon essential oil collection is certified USDA guaranteeing that, the new line ...
Breaking Medicine News(10 mins):